194 related articles for article (PubMed ID: 36866838)
1. Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
Lesokhin A; LeBlanc R; Dimopoulos MA; Capra M; Carlo-Stella C; Karlin L; Castilloux JF; Forsberg P; Parmar G; Tosikyan A; Pour L; Ribrag V; Ribolla R; Abdallah AO; Le Roux N; Dong L; van de Velde H; Mayrargue L; Lépine L; Macé S; Moreau P
Cancer Med; 2023 May; 12(9):10254-10266. PubMed ID: 36866838
[TBL] [Abstract][Full Text] [Related]
2. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
[TBL] [Abstract][Full Text] [Related]
3. Isatuximab: A Review of Its Use in Multiple Myeloma.
Frampton JE
Target Oncol; 2021 Sep; 16(5):675-686. PubMed ID: 34351561
[TBL] [Abstract][Full Text] [Related]
4. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
[TBL] [Abstract][Full Text] [Related]
5. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
Dimopoulos M; Bringhen S; Anttila P; Capra M; Cavo M; Cole C; Gasparetto C; Hungria V; Jenner M; Vorobyev V; Ruiz EY; Yin JY; Saleem R; Hellet M; Macé S; Paiva B; Vij R
Blood; 2021 Mar; 137(9):1154-1165. PubMed ID: 33080623
[TBL] [Abstract][Full Text] [Related]
6. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.
Martin TG; Capra M; Mohty M; Suzuki K; Quach H; Cavo M; Moreau P; Dimopoulos M; Yong K; Tekle C; Foster MC; Barnes Y; Risse ML; Mikhael J
Transplant Cell Ther; 2023 Feb; 29(2):134.e1-134.e7. PubMed ID: 36372355
[TBL] [Abstract][Full Text] [Related]
7. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
[TBL] [Abstract][Full Text] [Related]
8. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
Piggin A; Prince HM
Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
[TBL] [Abstract][Full Text] [Related]
10. Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma.
Banerjee R; Lo M; Martin TG
Future Oncol; 2021 Dec; 17(35):4849-4860. PubMed ID: 34553603
[TBL] [Abstract][Full Text] [Related]
11. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Richardson PG; Perrot A; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Malinge L; Dubin F; van de Velde H; Anderson KC
Lancet Oncol; 2022 Mar; 23(3):416-427. PubMed ID: 35151415
[TBL] [Abstract][Full Text] [Related]
12. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
[TBL] [Abstract][Full Text] [Related]
13. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Risse ML; Asset G; Macé S; Martin T;
Lancet; 2021 Jun; 397(10292):2361-2371. PubMed ID: 34097854
[TBL] [Abstract][Full Text] [Related]
14. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
Facon T; Moreau P; Špicka I; Suzuki K; Yong K; Mikhael J; Fukao T; Bisht K; Armstrong NM; Macé S; Risse ML; Martin T
Hematol Oncol; 2024 Mar; 42(2):e3258. PubMed ID: 38402467
[TBL] [Abstract][Full Text] [Related]
15. Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
Sunami K; Ikeda T; Huang SY; Wang MC; Koh Y; Min CK; Yeh SP; Matsumoto M; Uchiyama M; Iyama S; Shimazaki C; Lee JH; Kim K; Kaneko H; Kim JS; Lin TL; Campana F; Tada K; Iida S; Suzuki K;
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e751-e761. PubMed ID: 35641409
[TBL] [Abstract][Full Text] [Related]
16. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Harrison SJ; Perrot A; Alegre A; Simpson D; Wang MC; Spencer A; Delimpasi S; Hulin C; Sunami K; Facon T; Vlummens P; Yong K; Campana F; Inchauspé M; Macé S; Risse ML; van de Velde H; Richardson P
Br J Haematol; 2021 Jul; 194(1):120-131. PubMed ID: 34036560
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
[No Abstract] [Full Text] [Related]
18. Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma.
Shah B; Gray J; Abraham I; Chang M
J Oncol Pharm Pract; 2023 Jan; 29(1):170-182. PubMed ID: 35726199
[TBL] [Abstract][Full Text] [Related]
19. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
Sunami K; Suzuki K; Ri M; Matsumoto M; Shimazaki C; Asaoku H; Shibayama H; Ishizawa K; Takamatsu H; Ikeda T; Maruyama D; Kaneko H; Uchiyama M; Kiguchi T; Iyama S; Murakami H; Takahashi K; Tada K; Macé S; Guillemin-Paveau H; Iida S
Cancer Sci; 2020 Dec; 111(12):4526-4539. PubMed ID: 32975869
[TBL] [Abstract][Full Text] [Related]
20. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.
Shen F; Shen W
Technol Cancer Res Treat; 2022; 21():15330338221106563. PubMed ID: 35903924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
